Drug Type Fusion protein |
Synonyms INES 103, INES-103, INES103 |
Target- |
Mechanism ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | US | 22 Dec 2022 | |
Solid tumor | Phase 1 | US | 22 Dec 2022 | |
Hematologic Neoplasms | IND Approval | CN | 05 Jan 2023 |